Trial Profile
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Dec 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 05 Sep 2005 New trial record.